After demand for its COVID-19 shots plummeted, its new treatment for melanoma has reversed the Mass. company’s fortunes.

Moderna has been looking for its next blockbuster drug after a wildly successful COVID era.

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

In addition to melanoma, Moderna and Merck are conducting trials with personalized injections to fight types of bladder, ...

Moderna's shares soared during the Covid vaccine boom before crashing as demand faded. A cancer breakthrough has now ...

A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said<a class="excerpt-read-more" href=" More ...

The company said a critical late-stage study of an experimental vaccine showed the treatment stopped melanoma from spreading.

Moderna’s stock delivered one of the year’s biggest shocks to bearish investors after surging 177% in a single session, wiping out an estimated $5.5 billion from short sellers who had bet against the ...

Moderna and Merck's personalized mRNA cancer vaccine has achieved the first positive Phase 3 result of its kind.